<DOC>
	<DOCNO>NCT01631422</DOCNO>
	<brief_summary>This single-center , open-label study investigate pharmacokinetics elimination radiolabelled dose RO4602522 healthy male volunteer . The healthy male volunteer receive single oral dose RO4602522 .</brief_summary>
	<brief_title>A Single Dose Study Radiolabeled RO4602522 Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy male volunteer , 35 55 year age , inclusive Healthy status define absence evidence active chronic disease follow detailed medical surgical history , complete physical examination include vital sign , 12lead electrocardiogram ( ECG ) , hematology , blood chemistry , serology urinalysis A body mass index ( BMI ) 18 30 kg/m2 inclusive Male volunteer partner childbearing potential must use 2 method contraception , one must barrier method duration study 90 day last dose . Able participate willing give write informed consent comply study restriction . Nonsmokers smoke since least 3 month prior screen If capable reproduction , unwilling use effective form contraception Suspicion regular consumption drug abuse and/or positive drug alcohol screen Infection hepatitis B , hepatitis C , human immunodeficiency virus 1 2 Systolic blood pressure great 140 less 90 mm Hg , diastolic blood pressure great 90 less 50 mm Hg Resting pulse rate great 90 less 45 beat per minute Clinically significant abnormality laboratory test result Participation investigational drug device study within 90 day prior screen Donation blood within 3 month prior screen Concomitant disease condition could interfere , treatment might interfere , conduct study , would , opinion investigator , pose unacceptable risk subject study</criteria>
	<gender>Male</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>